Skip to content

GRAIL, Inc. GRAL Preferred Stock

Preferred Stock at other companies

Guardant Health logo
Guardant HealthGH
$0
Erasca, Inc. logo
Erasca, Inc.ERAS
$0
GeneDx Holdings logo
GeneDx HoldingsWGS
$0
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$0
Exelixis logo
ExelixisEXEL
$0
Incyte logo
IncyteINCY
$0

Other financials

Income statement

See full
Revenue$40.8M+28.1%
Operating income-$135.8M+11.6%
Net income-$93.2M+12.3%
EPS (diluted)-$2.29+26.1%

Balance sheet

See full
Cash & equivalents$76.3M-44.4%
Total debt$51.0M-20.7%
Total equity$2.5B+3.6%
Total assets$2.8B-1.5%

Cash flow

See full
Operating cash flow-$87.0M+8.4%
CapEx$503.0K+711%
Free cash flow-$87.5M+8.0%

Valuation

See full
Market cap$2.62B+145%
Enterprise value$2.6B+164%
P/S16.8×+8.6×

Profitability

See full
Operating margin-348.7%-153pp
Net margin-253.2%-115pp
FCF margin-187.2%-60.4pp

Returns & leverage

See full
Return on equity-16.1%
Debt / equity0.0×
Current ratio11.7×+2.0×

Where this comes from

Reported directly by GRAIL, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: GRAIL, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about GRAIL, Inc.'s preferred stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GRAIL, Inc.'s preferred stock?
GRAIL, Inc. (GRAL) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?
Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.